Corporation (Nasdaq:ARWR) announced today the appointment of Dr. Lee Hartwell
to its Scientific Advisory Board. Dr. Hartwell is a well-known expert in cancer
biology and was awarded the Nobel Prize in Medicine in 2001 for his ground-breaking
work in cell cycle regulation. Dr. Hartwell is President of the Fred Hutchinson
Cancer Research Center in Seattle, Washington. His insights into cell cycle
control are being used at the Hutchinson Center and elsewhere to develop treatments
for cancer and other diseases.
“Dr. Hartwell is one of the great scientific thought leaders of our
time, and we are honored to have him as part of our team,” said Arrowhead
President and CEO, Dr. Christopher Anzalone. “He will play a large role
helping to focus our strategy and extend our scientific reach as we look forward
to new opportunities and initiatives.”
“I am committed to improving patient outcomes and reducing healthcare
costs through improved molecular diagnostics,” said Dr. Hartwell. “Arrowhead
has the potential to bring together the technologies that can implement molecular
diagnostics at the point of care and it is an exciting opportunity for me to
participate in that vision."
Dr. Hartwell joins Drs. Chad Mirkin, Mauro Ferrari, and Tom Tombrello on Arrowhead’s
Scientific Advisory Board. These are some of the world’s most prolific
pioneers in nanotechnology and medicine, and they are tasked with helping to
develop a dynamic scientific roadmap to guide Arrowhead’s CEO in establishing
the Company as the preeminent outlet for commercializing revolutionary advances
in the field. The Scientific Advisory Board provides broad scientific direction
for the Company, as well as very specific recommendations with respect to technologies
that could serve as the basis for new companies, technologies that could augment
the scientific and market positions of existing subsidiaries, and recruiting
world-class personnel for Arrowhead and its subsidiaries. In addition, these
thought leaders have deep relationships within academia and industry, and will
be critically involved in establishing partnerships for Arrowhead and its subsidiaries.
Dr. Hartwell is involved in national and international projects to increase
the number of laboratories working in protein diagnostics, develop more team
science, improve the availability of informatics for data sharing, provide standardized
reagents and stimulate new technology development. Dr. Hartwell is the recipient
of many national and international scientific awards. His honors include the
Albert Lasker Basic Medical Research Award, the Gairdner Foundation International
Award and the Alfred P. Sloan Award in cancer research. He is a member of the
National Academy of Sciences. He earned his B.S. at the California Institute
of Technology and his Ph.D. from the Massachusetts Institute of Technology.
He joined the University of Washington faculty in 1968 and has been a genetics
professor there since 1973. In 1996, he joined the faculty of Seattle's Fred
Hutchinson Cancer Research Center and, in 1997, became its president and director.
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanotechnology company commercializing
new technologies in the areas of life sciences and electronics. Arrowhead is
seeking to build value for shareholders through the progress of its subsidiaries
and investments. Currently, Arrowhead is focused primarily on its two majority
owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic
applications, and Calando, at the forefront of clinical application of RNAi
delivery technology. Arrowhead also has minority investments in two privately
held nanobiotech companies.